Abstract
The Tesamorelin (TH9507) is an analogue of GHRH (a "signal" that tells the pituitary gland to release GH). In controlled human studies, the most consistent result is: reduction of visceral fat (VAT(the "deeper" fat around the organs) over ~26 weeks, with an expected parallel effect: IGF-1 in the blood rises (a point of monitoringnot a "trophy"). This article takes the literature and translates it into operational S157 reading: what's solid, what varies, how to read VAT vs markers in the blood and where the red flags (method, measurement and interpretation).
1) What it is (GHRH → GH/IGF-1) - 2) What human studies show (VAT/IGF-1) - 3) Graphs + table (auditable) - 4) Timing (half-life vs duration) - 5) Security and monitoring - 6) S157 mini-framework - Related Database Profiles - References
Before you interpret "effect", eliminate false operational signals:
- Lab Tools - consistency of the process (reconstitution, concentration, recording).
- U-100 Calculator - scale reading and Type A/B error prevention.
- COA Auditor - traceability, batch, method and structured audit.
1) Core concept: what Tesamorelin does (without exaggeration)
Tesamorelin is a GHRH analogue. In plain language: he "pulls the trigger" on the normal axis to release GH and consequently rise IGF-1. This is important for two practical reasons:
- Signal shape: works via the endogenous axis (tends to respect the logic of pulses), instead of "forcing" a constant baseline level.
- The most repeated human result: VAT ↓ (visceral fat measured by imaging) in controlled trials.
Quick terms: VAT = visceral fat (deeper, around the organs). Not the same as subcutaneous fat (what you "see" on the outside). For definitions (GHRH, GH, IGF-1, VAT, pulsatile vs continuous), use the S157 Lexicon (search for "GHRH", "IGF-1", "VAT").
2) Human evidence: what is consistent (and what tends to vary)
In clinical trials (specific medical context), the overall picture is consistent: VAT reduced after ~26 weeks in the Tesamorelin arm, and IGF-1 rises. Metabolic" (glycaemia, lipids, inflammation), on the other hand, appears with more favourable results. mixed because it depends a lot on: who has been studied, what was measured and as was measured.
Note S157: "repeats" does not mean "guarantees". It means that it appears several times when the design is checked and the measurement is solid.
3) Graphs + table (auditable): VAT and IGF-1 at ~26 weeks
Below is a summary visual (graphs) and a summary numerical (table) with the 26-week data from the clinical trials described in the public documentation. It is not a meta-analysis and does not "promise" an individual effect - it serves to read the shape of the signal and avoid misinterpretations.
Note: figures above are averages at ~26 weeks as described in public documentation (see "References").
4) Timing: the classic error (half-life vs duration of effect)
This is where a lot of people get it wrong. Three different things:
- Half-lifeHow long it takes for the molecule to "halve" in the blood.
- Duration of effecthow long the body continues to respond (GH/IGF-1 and cascades that follow).
- When to measurewhen it makes sense to look at a marker (IGF-1) or a result (VAT imaging).
If you want to study timing, document the trio: when to measure (timing), useful window (duration of effect) and half-life (PK). If you don't separate these things, the analysis becomes noise.
5) Security and monitoring: what is a "checkpoint" (no drama)
The operational node here is IGF-1it goes up, and that's a signal to monitoring (not to celebrate blindly). The second knot is context: Tesamorelin is a medicine for medical use in specific clinical context and has contraindications/warnings.
- It's not "weight management"The public documentation itself describes a "weight-neutral" effect.
- Long term: long-term cardiovascular safety is a subject of caution in the documentation.
- Metabolic riskThere are warning signs for glucose intolerance/diabetes in some data (clinical monitoring).
- Other precautionsactive neoplasm, hypersensitivity, fluid retention, etc. (medical domain).
Educational content. Does not constitute medical advice. For risk reduction principles and guidelines, please consult the Information Use Policy.
6) S157 mini-framework (quick decision, no self-deception)
- Define what you're measuringVAT by image, body composition, blood markers, performance, or "sensation"?
- Define the methodVAT without CT/MRI becomes "history", not data. Method first, narrative later.
- Separate scoreboardIGF-1 is a marker (control point); VAT is a result measured by image.
- Audit the processconsistency of reconstitution, recording, and prevention of human error. (Lab Tools - U-100)
- Validate the materialWithout traceability and an analytical method, "99%" is not science. (COA Auditor)
- Confirm the context: the best human evidence comes from a specific clinical context - don't assume that it "transfers" to other scenarios without caution.
Related Database Profiles (6)
Insider SEO tip: also link this post to Peptide Database, to Research Journal and Lexicon (clusters: GH/IGF-1, timing, VAT, monitoring).
References
-
EGRIFTA SV (tesamorelin) - FDA Label / Prescribing Information (Revised 02/2024). Clinical study tables (VAT and IGF-1 at ~26 weeks).
Open PDF (FDA) - Peer-reviewed articles on tesamorelin on visceral fat (TC) endpoints and biomarkers (IGF-1) in a clinical context. (If you want, send 2-3 PubMed/DOI links that you prefer as "anchors" and I'll replace this line with specific citations, without messing with the layout).
Note S157: I've kept an official anchor (FDA) for the graph/table numbers. The rest can be "anchored" with PubMed/DOI according to your list.
Safety Note (S157): Educational content. Does not constitute medical advice. For risk reduction principles, please consult Information Use Policy.
EN 
PT 
FR 
ES 
DE 
IT 
PL